Skip to main content

Table 4 Correlations between baseline parameters and the reduction of body weight or HbA1c at 2 year

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Baseline parameters

Reduction of body weight

Reduction of HbA1c

  

Multivariate p value

 

Multivariate p value

 

r

p value

 

r

p value

 

Age

−0.080

0.601

 

−0.197

0.190

 

Male

−0.131

0.390

 

−0.052

0.732

 

BMI

0.474

0.001

0.018

0.134

0.382

 

WC

0.111

0.012

0.255

0.055

0.776

 

Duration of DM

0.076

0.651

 

−0.003

0.984

 

SBP

−0.106

0.490

 

0.003

0.982

 

DBP

−0.007

0.963

 

0.222

0.138

 

FPG

−0.115

0.451

 

−0.066

0.664

 

HbA1c

0.145

0.341

 

0.738

<0.001

<0.001

LDL-C

0.137

0.383

 

0.420

0.005

0.701

TG

0.156

0.319

 

0.202

0.188

 

HDL-C

0.024

0.880

 

−0.137

0.374

 

AST

0.073

0.660

 

0.044

0.790

 

ALT

0.002

0.988

 

0.232

0.120

 

sCPR

0.222

0.152

 

0.108

0.542

 

Insulin dose

0.345

0.023

0.027

−0.078

0.617

 

Insulin dose U/kg

0.022

0.152

 

−0.102

0.509

 

Eating behavior

−0.078

0.731

 

0.126

0.576

 

Previous treatment

Insulin

0.118

0.441

 

−0.176

0.242

 

BG

−0.153

0.316

 

−0.053

0.725

 

SU

−0.098

0.521

 

−0.250

0.094

0.996

αGI

−0.035

0.819

 

−0.006

0.969

 

TZD

0.190

0.212

 

−0.191

0.204

 

DPP4i

0.048

0.752

 

0.169

0.263

 

Glinide

−0.060

0.697

 

0.161

0.285

 
  1. Reduction of body weight or HbA1c from baseline to 2 year was analyzed with baseline clinical parameters.
  2. BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose, HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerides, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase, ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us